IL-31-Receptor‑α Antagonist Nemolizumab in Treatment‑Refractory Brachioradial Pruritus: A Case Report - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Nemolizumab, an IL-31 Receptor-α Antagonist, for Refractory Brachioradial Pruritus: A Case Report

  • By

  • Manuel P. Pereira

  • Eva M. Grekowitz

  • Martin Metz

  • November 20, 2026

Share

Clinical Scorecard: Nemolizumab for Refractory Brachioradial Pruritus: A Case Report

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Nemolizumab, an IL-31 Receptor-α Antagonist, for Refractory Brachioradial Pruritus
Key MechanismsBRP pathogenesis is thought to involve UV-related cutaneous nerve-fiber injury and cervical spine degeneration. The article describes IL-31 as a cytokine linking immune-cell activity and sensory-nerve stimulation, and as a potential therapeutic target.
Target PopulationPatients or participants described in the source article.
Care SettingCase-report clinical context: BRP was diagnosed from the characteristic presentation without cervical spine imaging; symptoms and quality-of-life measures were reported during 3 months of treatment follow-up.

Key Highlights

  • The patient had bilateral arm pruritus, burning, and pain for more than 4 years, with temporary relief from cold exposure.
  • Symptoms persisted despite topical treatments, gabapentin, pregabalin, and naltrexone.
  • After nemolizumab initiation, WI-NRS decreased from 7–9/10 to 3/10 within 10 days and was most often 0–1/10 thereafter.
  • DLQI and ItchyQoL scores declined markedly after the first dose and subsequently stabilized.
  • The report is limited to one case, concomitant antipruritic treatment, and a 3-month observation period.

Guideline-Based Recommendations

Diagnosis

  • The case diagnosis was based on the characteristic clinical presentation; cervical spine imaging was not performed.
  • The patient reported temporary symptom relief from cold exposure, consistent with a positive ice-pack sign.

Management

  • The article describes suggested management as avoiding triggers such as heat and using topical treatments, anticonvulsants, antidepressants, or opioid receptor modulators.
  • Nemolizumab was given as a 60 mg loading dose followed by 30 mg every 4 weeks, while pregabalin and naltrexone were continued.
  • The authors state that further studies are required before nemolizumab can be considered for selected individuals with severe, refractory BRP.

Monitoring & Follow-up

    Risks

      Patient & Prescribing Data

      One 65-year-old woman with more than 4 years of bilateral arm symptoms and inadequate sustained response to prior topical agents, gabapentin, pregabalin, and naltrexone.

      Nemolizumab was initiated at 60 mg, then continued at 30 mg every 4 weeks alongside established pregabalin and naltrexone. Itch improved within 10 days and remained low during the reported 3-month follow-up.

      Clinical Best Practices

      • The case involved characteristic BRP symptoms and distribution, with temporary relief from cold exposure.
      • Examination showed lichenification and excoriations; biopsy findings were compatible with chronic scratch lesions.
      • The case tracked itch severity using WI-NRS and quality of life using DLQI and ItchyQoL.
      • The authors note that the response cannot be attributed to nemolizumab independently of concomitant treatment and that follow-up was brief.

      Related Resources & Content

        Original Source(s)

        Related Content